News
ATXS
13.75
+1.93%
0.26
KalVista Pharmaceuticals: The Share Price Rally Requires An Adjustment Of My Investment Thesis
Seeking Alpha · 6d ago
Astria Therapeutics: Tailwinds Building With Novel Treatment Paradigm
Seekingalpha · 12/24/2022 05:38
BRIEF-Deep Track Capital Reports 7.32% Passive Stake In Astria Therapeutics As Of December 15, 2022 - SEC Filing
Reuters · 12/22/2022 21:08
MillerKnoll, Cleveland-Cliffs And Some Other Big Stocks Moving Higher On Thursday
Benzinga · 12/22/2022 15:57
$10 Million Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
Benzinga · 12/22/2022 13:35
Moderna To Rally Over 42%? Here Are 10 Other Price Target Changes For Monday
Benzinga · 12/19/2022 13:29
HC Wainwright & Co. Maintains Buy on Astria Therapeutics, Raises Price Target to $20
Benzinga · 12/19/2022 11:14
--HC Wainwright Adjusts Astria Therapeutics Price Target to $20 From $13, Maintains Buy Rating
--HC Wainwright Adjusts Astria Therapeutics Price Target to $20 From $13, Maintains Buy Rating
MT Newswires · 12/19/2022 07:59
Dow Dips Over 800 Points; S&P 500 Down 2.8%
Benzinga · 12/15/2022 19:26
Why Third Harmonic Bio Shares Are Trading Lower By Over 78%? Here Are 40 Stocks Moving In Thursday's Mid-Day Session
Benzinga · 12/15/2022 18:28
RCI Hospitality, AbCellera Biologics And Some Other Big Stocks Moving Higher On Thursday
Benzinga · 12/15/2022 15:41
Astria Therapeutics' Potential Hereditary Angioedema Candidate Shows Encouraging Action In Healthy Participants
Benzinga · 12/15/2022 14:14
Wedbush Adjusts Astria Therapeutics Price Target to $27 From $16, Maintains Outperform Rating
Wedbush Adjusts Astria Therapeutics Price Target to $27 From $16, Maintains Outperform Rating
MT Newswires · 12/15/2022 11:46
Astria Therapeutics Announces Preliminary Results From The Phase 1a Clinical Trial Of STAR-0215 In Healthy Subjects
Benzinga · 12/15/2022 11:02
Astria Therapeutics Prices $100 Million Common Stock Offering
Astria Therapeutics Prices $100 Million Common Stock Offering
MT Newswires · 12/15/2022 06:41
Astria TherapeuticS GAAP EPS of -$0.87 beats by $0.05
Seekingalpha · 11/10/2022 22:46
Astria Therapeutics Q3 EPS $(0.87) Down From $(0.61) YoY
Benzinga · 11/10/2022 22:05
-- Earnings Flash (ATXS) ASTRIA THERAPEUTICS Reports Q3 Loss $-0.87
-- Earnings Flash (ATXS) ASTRIA THERAPEUTICS Reports Q3 Loss $-0.87
MT Newswires · 11/10/2022 16:22
Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference
BOSTON, Mass., November 09, 2022--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological dise...
Business Wire · 11/09/2022 13:00
Astria Therapeutics To Present STAR-0215 Modeling And Simulation Data At The 2022 American College Of Allergy, Asthma And Immunology Annual Meeting
Benzinga · 11/07/2022 13:15
More
Webull provides a variety of real-time ATXS stock news. You can receive the latest news about Astria Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About ATXS
Astria Therapeutics, Inc. is a biopharmaceutical company focused on discovering, developing and commercialization of therapies to patients and families affected by rare and niche allergic and immunological diseases. The Company’s lead product candidate is STAR-0215, is a potential monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema (HAE). HAE is a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen and airway. STAR-0215 is a monoclonal antibody inhibitor of plasma kallikrein, which is designed to provide long-acting attack prevention for HAE. The Company’s on-demand treatment of HAE therapy includes BERINERT, FIRAZYR, KALBITOR and RUCONEST. Its long-term preventative treatment of HAE therapy includes CINRYZE, HAEGARDA, TAKHZYRO and ORLADEYO.